ZBiotics, a San Francisco, CA-based company offering a new category of genetically engineered probiotics, raised $12M in Series A funding.
The round was led by Spring Tide Capital with participation from Access Capital, Seamless Capital, Goat Rodeo Capital, and Seaside Ventures.
The company intends to use the funds to expand distribution and bring new GMO probiotics to market.
Led by CEO Zack Abbott, ZBiotics is a maker of genetically engineered probiotics, purpose-built to improve health, starting with helping bodies handle the arising biological challenges of modern living. The company’s flagship product, Pre-Alcohol Probiotic Drink, mimics the function of the liver by breaking down the toxic byproduct of alcohol, acetaldehyde, helping consumers feel better the day after drinking.
The company will utilize the funds to develop and bring additional use-case probiotics to market, leveraging the same technology used to develop its Pre-Alcohol Probiotic Drink to create additional solutions for consumers looking to prioritize different aspects of their health. In addition to its flagship product, ZBiotics will be launching its second product in the coming weeks, which will focus on microbial diversity in the gut and associated benefits. Research and development at the company is also actively exploring products that will address a range of concerns like sleep, vaginal health and athletic performance. The funds will also be used to launch the ZBiotics brand into physical retail spaces.
FinSMEs
27/08/2024